SGT 601
Alternative Names: AVB-501; SGT-601Latest Information Update: 14 Apr 2023
At a glance
- Originator Avanti Biosciences
- Developer Solid Biosciences
- Class Cardiovascular therapies; Gene therapies
- Mechanism of Action Gene transference; Troponin T replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Dilated cardiomyopathy
Highest Development Phases
- Preclinical Dilated cardiomyopathy